Compound Structure
Molecular structure serves as the starting point for mechanistic safety modeling.
Platform
CYTOCAST DIGITAL TWIN Platform™ for Predictive Drug Safety
Mechanistic AI and systems-level biological simulation for interpretable prediction of clinically relevant drug side effects.
From compound structure to off-targets, pathways, tissues, and clinical outcomes, Cytocast models how drug-induced biological perturbations propagate across interconnected human systems.
Platform Architecture
How the CYTOCAST DIGITAL TWIN Platform™ functions
The CYTOCAST DIGITAL TWIN Platform™ combines three integrated computational engines to connect molecular interactions, systems-level biological perturbations, and clinically observed adverse outcomes, enabling mechanistic modeling of how drug-induced perturbations may translate into real clinical side effects.
Off-Target Predictor
AI-powered prediction of target affinity and off-target interaction profiles for early mechanistic safety assessment.
- Binding affinity estimation
- Off-target prioritization
DIGITAL TWIN Cell™ Simulation
Predicted molecular interactions are propagated through biological networks to identify significant perturbations across protein complexes, pathways, and tissues.
- 7,700+ modeled proteins
- Whole-cell systems modeling
- Multi-tissue biological simulation
Clinical Side Effect Prediction
Perturbation signatures are mapped to clinically observed adverse outcomes across MedDRA PT endpoints.
- 1000+ clinically observed side effects
- Mechanistically linked predictions
- Clinically grounded endpoints
Confidence & Mechanistic Interpretation
Predicted side effects are stratified into confidence tiers and linked back to mechanistic biological explanations.
- Confidence stratification
- Mechanistic traceability
- Tissue-level interpretation
- Ranked risk outputs
Mechanistic traceability and biological interpretation
Deployment
Designed for pharmaceutical R&D environments
Secure collaborative deployments
API-compatible integration pathways
Scalable compound screening workflows
Flexible deployment configuration for evolving R&D needs
Designed to support integration into modern drug discovery, translational safety assessment, and mechanistic decision-making workflows across pharmaceutical and biotech R&D environments.
Cytocast Report
Mechanistic safety reports designed for decision-making
The CYTOCAST Report converts complex mechanistic simulation outputs into interpretable, decision-oriented safety insight for pharmaceutical R&D teams.
- Ranked side-effect risks
- Affected targets and off-targets
- Perturbed pathways and biological complexes
- Tissue-level interpretation
- Mechanistic traceability
- Confidence-tiered predictions
- Translational safety rationale
- Comparative candidate analysis
- Mechanistic feature attribution
Why Mechanistic Modeling Matters
Mechanistic modeling beyond statistical correlation
Most current drug safety prediction approaches primarily learn statistical associations between molecular features and observed outcomes, with limited representation of the biological mechanisms underlying clinical side effects.
Cytocast instead models how drug-induced perturbations propagate across targets, pathways, tissues, and interconnected biological systems to generate clinically relevant adverse outcomes.
Compound structure
Targets & off-targets
Pathway perturbation
Confidence tiers
Clinically observed side effects
This enables:
Mechanistically interpretable safety reasoningBiological traceabilityTranslational risk assessmentMechanistically informed prioritizationEarlier actionable decision-making
The result is a mechanistically connected safety interpretation framework designed to support real pharmaceutical R&D decisions.
Product Applications
Three products. One integrated safety layer.
Cytocast Screener™
- Decision:
- Which compounds should be eliminated early?
- Stage:
- Hit -> Lead
- Output:
- High-throughput safety triage with early mechanistic risk signals.
- Use Case:
- Rapid identification of compounds with predicted clinically relevant liabilities prior to expensive synthesis and experimental validation.
Cytocast Optimizer™
- Decision:
- Which candidate has the best safety profile?
- Stage:
- Lead Optimization
- Output:
- Comparative mechanistic safety ranking across candidates.
- Use Case:
- Comparative mechanistic profiling supporting prioritization, medicinal chemistry design decisions, and safety differentiation between candidates.
Cytocast Nominator™
- Decision:
- Which candidate should advance toward IND?
- Stage:
- Preclinical / IND-Enabling
- Output:
- Decision-grade mechanistic safety interpretation.
- Use Case:
- Mechanistically interpretable safety assessment supporting translational risk evaluation and candidate nomination.
Validation and Confidence Framework
1000+ Clinically observed side effects
~0.70 Median balanced accuracy for Gold-tier predictions
7,700+ Proteins modeled across 29 tissues
Strong Benchmark performance in binding affinity and off-target prediction tasks
Benchmark References
FlowDock BOLTZ-2Confidence-Tiered Safety Interpretation
Gold Tier
Well-supported, high-confidence side effects with strong mechanistic and predictive support.
Silver Tier
Moderate-confidence signals requiring contextual interpretation or focused validation.
Bronze Tier
Exploratory or lower-confidence mechanistic observations.
Interpretation
Decision-oriented signals suitable for prioritization and early portfolio decision-making.
Potential liabilities warranting targeted experimental follow-up or mechanistic review.
Signals potentially useful for broader safety monitoring, hypothesis generation, or future investigation.